chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 18.0
Sex: F
Vaccine: COVID19
Symptoms: Chest pain, Dyspnoea, Fatigue, Headache
Clinical narrative: She had a headache and fatigue the day after the vaccination; She had a headache and fatigue the day after the vaccination; In the evening on Wednesday she said it hurt to breath deeply for a few hours (about 7 to 10pm); Described it as a stabbing pain in chest; This is a spontaneous report from a contactable consumer. A 18-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via intramuscular route of administration in the right arm on 20Apr2021 at 14:45 (at the age of 18-years-old) as a single dose for COVID-19 immunisation. Medical history included seasonal allergies, and penicillin allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications taken within two weeks of vaccination included cetirizine hydrochloride (ZYRTEC) and ethinylestradiol, norgestimate (TRI-SPRINTEC); both for unknown indication, and acne medicine; all from unknown date for unknown indication and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN5318) via intramuscular route of administration in the right arm on 31Mar2021 at 16:45 (at the age of 18-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient had a headache and fatigue on 21Apr2021 at 08:00, the day after the vaccination. On 21Apr2021, in the evening on Wednesday the patient said it hurt to breathe deeply for a few hours (about 19:00 to 22:00). The patient described it as a stabbing pain in her chest. By Thursday her symptoms were gone. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events headache and fatigue the day after the vaccination; in the evening on Wednesday the patient said it hurt to breathe deeply for a few hours (about 19:00 to 22:00); the patient described it as a stabbing pain in her chest; by Thursday her symptoms were gone was resolved on 22Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Fatigue, Gait disturbance, Nausea, Pain
Clinical narrative: At times unable to walk around house; Extreme body aches-at times unable to walk around house; Fever at 102.7 or higher for 48/56 hours; Nausea; Vomitting; Extreme fatigue; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 26Mar2021 at 12:00 (at the age of 45-year-old), as a single dose for COVID-19 immunisation. Medical history included fibromyalgia, high blood pressure (bp), asthma, obstructive sleep apnea (OSA) and obesity. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included hydrochlorothiazide; losartan potassium (losartan HCTZ) (MANUFACTURER UNKNOWN), duloxetine hydrochloride (CYMBALTA) and meloxicam (MANUFACTURER UNKNOWN), all on an unknown date for unknown indication and unknown if ongoing. On 26Mar2021 at 18:00, the patient experienced fever at 102.7 or higher for 48/56 hours, nausea/vomiting, extreme fatigue and extreme body aches-at times unable to walk around house. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. On the same day, the patient underwent body temperature test and the result was found to be 102.7 or higher (unspecified units). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever at 102.7 or higher for 48/56 hours, nausea/vomiting, extreme fatigue and extreme body aches-at times unable to walk around house was recovering at the time of this report. The patient also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 18Apr2021 at 11:00 (at the age of 45-year-old), as a single dose for COVID-19 immunisation.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, Vomiting
Clinical narrative: At times unable to walk around house; Extreme body aches-at times unable to walk around house; Fever at 102.7 or higher for 48/56 hours; Nausea; Vomitting; Extreme fatigue; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 26Mar2021 at 12:00 (at the age of 45-year-old), as a single dose for COVID-19 immunisation. Medical history included fibromyalgia, high blood pressure (bp), asthma, obstructive sleep apnea (OSA) and obesity. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included hydrochlorothiazide; losartan potassium (losartan HCTZ) (MANUFACTURER UNKNOWN), duloxetine hydrochloride (CYMBALTA) and meloxicam (MANUFACTURER UNKNOWN), all on an unknown date for unknown indication and unknown if ongoing. On 26Mar2021 at 18:00, the patient experienced fever at 102.7 or higher for 48/56 hours, nausea/vomiting, extreme fatigue and extreme body aches-at times unable to walk around house. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. On the same day, the patient underwent body temperature test and the result was found to be 102.7 or higher (unspecified units). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever at 102.7 or higher for 48/56 hours, nausea/vomiting, extreme fatigue and extreme body aches-at times unable to walk around house was recovering at the time of this report. The patient also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 18Apr2021 at 11:00 (at the age of 45-year-old), as a single dose for COVID-19 immunisation.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoaesthesia, Paraesthesia
Clinical narrative: Numbness and tingling in little, ring and middle fingers on side that injection was (left upper arm); Numbness and tingling in little, ring and middle fingers on side that injection was (left upper arm); This is a spontaneous report from a contactable consumer, the patient. A 31-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0172) via an unspecified route of administration in the left arm on 26Apr2021 at 11:30 (at the age of 31-years-old) as a single dose for COVID-19 immunisation. Medical history included depression, anorexia, bradycardia and known allergy to latex and sulfa. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included fluoxetine (MANUFACTURER UNKNOWN), gabapentin (MANUFACTURER UNKNOWN) and spironolactone (MANUFACTURER UNKNOWN); all from unknown date for unknown indication and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 05Apr2021 at 11:30 (at the age of 31-years-old) as a single dose for COVID-19 immunisation and received amoxicillin antibiotics (MANUFACTURER UNKNOWN) for unknown indication on unknown date and experienced drug allergy. On 26Apr2021 at 11:45, the patient experienced numbness and tingling in little, ring and middle fingers on side that injection was (left upper arm),which the patient noticed after she had left the observation area and returned to her vehicle. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events numbness and tingling in little, ring and middle fingers on side that injection was (left upper arm) was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Blood test, Lymphadenopathy, Ultrasound scan
Clinical narrative: Right supraclavicular lymph node enlargement; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 13Apr2021 at 23:45 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. The medical history included moderate degeneration in left C5-C6, severe arthritis in right temporomandibular joints (TMJ),dermo procedures for nevus, basil cell, once melanoma insitu and allergy to adhesive bandages. The patient was healthy otherwise. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The concomitant medications included estradiol patch and cream (MANUFACTURER UNKNOWN), medroxyprogesterone (MANUFACTURER UNKNOWN) and calcium (MANUFACTURER UNKNOWN), all from unknown dates for unknown indications and unknown if ongoing. On 20Apr2021, the patient experienced right supraclavicular lymph node enlargement. On an unknown date, the patient underwent blood test and ultrasound and the result was unknown. The adverse events resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event right supraclavicular lymph node enlargement was not resolved at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site reaction
Clinical narrative: Raised red patch. Sore and hot to the touch. Vaccine site reaction 3 inches x 1 inch.; This is a spontaneous report from a non-contactable consumer, the patient. A 53-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown) via an unspecified route of administration in the left arm on 17Apr2021 at 16:00 (at the age of 53-year-old) as a single dose for COVID-19 immunisation. Medical history included unspecified allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. The concomitant medications included escitalopram (MANUFACTURER UNKNOWN) for an unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown) via an unspecified route of administration in the right arm on 20Mar2021 at 14:30 as a single dose for COVID-19 immunisation. On 20Apr2021 at 19:30, the patient experienced raised red patch, sore and hot to the touch and the vaccine site reaction of 3 inches x 1 inch. The events did not result in doctor or other healthcare professional office or clinic visit, emergency room or department or urgent care. No therapeutic measures were taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event raised red patch, sore and hot to the touch, vaccine site reaction 3 inches x 1 inch was not recovered at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Vomiting
Clinical narrative: Vomiting; Chills; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 26Apr2021 at 13:15 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. Medical history included diabetes, asthma, common variable immunodeficiency (CVID), penicillin allergy and peanut allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient had received other vaccines within four weeks prior to the vaccination which included a PFIZER vaccine (unspecified) via an unspecified route of administration in the right arm on 02Apr2021 (at the age of 51-years-old) for unknown indication. On 26Apr2021 at 19:00, the patient experienced vomiting and chills. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events which included treatment with promethazine (PHENERGAN). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events vomiting and chills was resolving at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 22.0
Sex: M
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site induration, Vaccination site rash, Vaccination site reaction, Vaccination site swelling
Clinical narrative: Delayed injection site reaction.; Delayed injection site reaction/ Baseball diameter redness; Delayed injection site reaction/ Rash; Delayed injection site reaction/ Swelling, Firm but not painful; Delayed injection site reaction/ Swelling, Firm but not painful; This is a spontaneous report from a contactable consumer, the patient. A 22-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0170) via an unspecified route of administration in the left arm on 16Apr2021 at 13:00(at the age of 22-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the left arm on 26Mar2021 at 13:00(at the age of 22-years-old) as a single dose for COVID-19 immunisation. On 26Apr2021 at 21:30 the patient experienced delayed injection site reaction, baseball diameter redness, rash and swelling, firm but not painful. Therapeutic measures were not taken as a result of events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events delayed injection site reaction, baseball diameter redness, rash and swelling, firm but not painful was resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Blood test, Culture, Dysphagia, Mouth ulceration, Oesophagitis
Clinical narrative: Horrible sore throat; Scratchy tongue; Esophagitis; Mouth ulcers; Difficult to swallow; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 18Apr2021 at 12:00 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Medical history included depression, chronic pain (reported as recovering), spinal lumbar fusion, allergy to penicillin, allergy to latex and allergy to food. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included escitalopram oxalate (LEXAPRO), alprazolam (XANAX), ethinylestradiol / ferrous fumarate / norethisterone acetate (LO LOESTRIN FE), topiramate (TOPAMAX) and gabapentin (GABAPENTIN) all for unknown indication from an unknown date and unknown if ongoing. The patient previously took nabumetone and metronidazole (FLAGYL) for unknown indication on an unknown date experienced drug allergy. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 28Mar2021 at 16:00 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. On 20Apr2021 at 00:30, the patient experienced horrible sore throat, scratchy tongue, esophagitis, mouth ulcers and difficult to swallow. The events resulted in emergency room/department or urgent care. Therapeutic measures were taken as a result of events and included treatment with antibiotics and mouth washes (unspecified). Since the vaccination, the patient had been tested for COVID-19. On 26Apr2021, the patient underwent SARS CoV-2 test via nasal swab and the result was pending. On an unknown date, the patient underwent blood work and culture tests and the result were unknown. The clinical outcome of the events horrible sore throat, scratchy tongue, esophagitis, mouth ulcers and difficult to swallow was not recovered at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Oropharyngeal pain, SARS-CoV-2 test, Tongue pruritus
Clinical narrative: Horrible sore throat; Scratchy tongue; Esophagitis; Mouth ulcers; Difficult to swallow; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 18Apr2021 at 12:00 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Medical history included depression, chronic pain (reported as recovering), spinal lumbar fusion, allergy to penicillin, allergy to latex and allergy to food. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included escitalopram oxalate (LEXAPRO), alprazolam (XANAX), ethinylestradiol / ferrous fumarate / norethisterone acetate (LO LOESTRIN FE), topiramate (TOPAMAX) and gabapentin (GABAPENTIN) all for unknown indication from an unknown date and unknown if ongoing. The patient previously took nabumetone and metronidazole (FLAGYL) for unknown indication on an unknown date experienced drug allergy. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 28Mar2021 at 16:00 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. On 20Apr2021 at 00:30, the patient experienced horrible sore throat, scratchy tongue, esophagitis, mouth ulcers and difficult to swallow. The events resulted in emergency room/department or urgent care. Therapeutic measures were taken as a result of events and included treatment with antibiotics and mouth washes (unspecified). Since the vaccination, the patient had been tested for COVID-19. On 26Apr2021, the patient underwent SARS CoV-2 test via nasal swab and the result was pending. On an unknown date, the patient underwent blood work and culture tests and the result were unknown. The clinical outcome of the events horrible sore throat, scratchy tongue, esophagitis, mouth ulcers and difficult to swallow was not recovered at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Axillary pain
Clinical narrative: Pain under arm after injection; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 10Apr2021 at 16:00 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history included hypothyroidism (Hypo thyroid). The patient had no known allergies. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 10Apr2021 at 16:00, the patient experienced pain under arm after injection. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event pain under arm after injection was resolving at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Oral herpes
Clinical narrative: 83 hours after receiving the second Pfizer Covid-19 vaccine, "I" developed a cold sore (herpes labialis); This is a spontaneous report from a contactable consumer, the patient. A 57-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the left arm on 23Apr2021 at 09:00 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. Medical history included type 2 diabetes, psoriasis, possible psoriatic arthritis and known allergies Penicillin. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included metformin (MANUFACTURER UNKNOWN) and vitamin d nos (MANUFACTURER UNKNOWN); both for an unknown indication from an unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 02Apr2021 at 09:00 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. On 27Apr2021 at 20:00, 83 hours after receiving the second Pfizer COVID-19 vaccine, the patient developed a cold sore (herpes labialis). This was the first cold sore she had in over 10 years. The patient had no unusual stress or disruption that might had contributed to this outbreak. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event 83 hours after receiving the second Pfizer COVID-19 vaccine, the patient developed a cold sore (herpes labialis) was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Ear pruritus, Eye swelling, Lip swelling
Clinical narrative: Bilateral eye swelling; Upper lip swelling; Left ear itchiness; This is a spontaneous report from a contactable nurse, the patient. A 45-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0171) via an unspecified route of administration in the left arm on 23Apr2021 at 15:15 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history included hypertension and known allergy to NSAIDs, crab and shrimp. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included labetalol (MANUFACTURER UNKNOWN), loratadine (MANUFACTURER UNKNOWN), vitamin d nos (MANUFACTURER UNKNOWN) and omeprazole (MANUFACTURER UNKNOWN); all for unknown indication from unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient previously received acetylsalicylic acid (ASPIRIN) and ibuprofen (MANUFACTURER UNKNOWN); both for unknown indication on unknown date and experienced drug allergy. On 23Apr2021 at 15:30, the patient experienced, bilateral eye swelling, upper lip swelling and left ear itchiness. The events resulted in emergency room/department or urgent care. Therapeutic measures were taken as a result of the events and included treatment with dexamethasone (MANUFACTURER UNKNOWN) and diphenhydramine hydrochloride (BENADRYL). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events bilateral eye swelling, upper lip swelling and left ear itchiness was unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Diarrhoea, Oropharyngeal pain, Vomiting
Clinical narrative: Sore throat; Diarrhea; Vomiting; This is a spontaneous report from a contactable consumer, the patient. A 46-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 22Apr2021 at 17:00 (at the age of 46-years-old) as a single dose for COVID-19 immunisation. Medical history included multiple sclerosis, HSCT autologous stem cell transplant (hematopoietic stem cell transplant) and known allergies to cantaloupe melon. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not take any concomitant medications. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. On 24Apr2021 at 04:30, 2 days after vaccine, the patient experienced diahrrea, vomiting and sore throat for 3 days. The events resulted in emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were not taken as a result of reported events. The clinical outcome of the events sore throat, diarrhea and vomiting was recovered on 26Apr2021.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Erythema, Pruritus, Urticaria
Clinical narrative: itching; hives; Redness was also noted to bilateral upper extremities and trunk.; This is a spontaneous report from a contactable pharmacist. A 64-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an intramuscular route of administration in the arm right on 14Apr2021 (at the age of 64-year-old) as a single dose for COVID-19 immunisation. Medical history included hypertension. The patient did not have any known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included NORVASC from an unknown date for an unknown indication and unknown if ongoing. On 14Apr2021, the patient experienced itching and hives during observation and redness was also noted to bilateral upper extremities and trunk. It was reported that vitals were within normal limits. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department, or urgent care. Therapeutic measures were taken as a result of the events included treatment with BENADRYL 12.5 mg and DEXAMETHASONE 4 mg per oral tablet. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events itching, hives, and redness to bilateral upper extremities and trunk were recovered on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Fatigue, Pain, Pyrexia
Clinical narrative: 102F Fever; Chills; Body ache; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EM0164) via an unspecified route of administration in the left arm on 22Apr2021 at 15:00 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. Medical history included obesity and penicillin allergy. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient previously received azithromycin (MANUFACTURER UNKNOWN) and experienced drug allergy. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 01Apr2021 at 13:30 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. On 23Apr2021 at 17:00, 26 hours after vaccination, the patient experienced 102F(Fahrenheit) fever, chills, body ache and fatigue. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of the events which included treatment with ibuprofen (MANUFACTURER UNKNOWN). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event fatigue was resolved on 23Apr2021, within 4 hours while that of the events 102F fever, chills and body ache was resolved on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 28.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Nausea, Pain in extremity
Clinical narrative: Hard time moving my right arm; Nauseous; Chills; This is a spontaneous report from a contactable consumer, the patient. A 28-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 26Apr2021 at 17:00 (at the age of 28-years-old) as a single dose for COVID-19 immunisation. Medical history included endometriosis with ovarian cyst and depression. The patient did not have any known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medication included unspecified birth control and anti-depression medications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 04Apr2021 at 15:45 (at the age of 28-years-old) as a single dose for COVID-19 immunisation. On 26Apr2021 at 21:00, the patient experienced hard time moving right arm, nauseous and chills. It was reported that the patient was able to sleep. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events hard time moving right arm, nauseous and chills were unknown at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Blood test, Body temperature, Body temperature increased, Chills, Gait disturbance
Clinical narrative: Sore tight muscles in arms and legs/ hard to get on/off toilet, hard to get up from sitting position; Sore tight muscles in arms and legs/hard to get on/off toilet, hard to get up from sitting position; Hard to walk, stopped taking stairs/ Hard to get on/off toilet, hard to get up from sitting position; Some days temperature will spike to 102; Cold chills; Hives; This is a spontaneous report from a contactable consumer, the patient. A 54-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6200) via an unspecified route of administration on 24Feb2021 at 09:00 (at the age of 54-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure, allergy to penicillin and sulfa. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medications included lisinopril (MANUFACTURER UNKNOWN) and cetirizine hydrochloride (ZYRTEC); both from an unknown date for an unknown indication. The patient previously received doxycycline (MANUFACTURER UNKNOWN) and cefdinir (MANUFACTURER UNKNOWN) and experienced drug allergy. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on an unknown date as a single dose for COVID-19 immunisation. On 26Feb2021, the patient experienced sore tight muscles in arms and legs, hard to get on/off toilet, hard to get up from sitting position, hard to walk, stopped taking stairs, some days temperature will spike to 102, sometimes got cold chills and have to get under 3-4 throws and sometimes have hives. It was reported that doctor did blood work which looked good and thought symptoms related to shot. It was reported that the patient had shot 9 weeks ago, at the time of this report. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events which included treatment with famotidine/ibuprofen (DUEXIS) 800 mg 3times a day. On an unknown date in 2021, the patient underwent body temperature test and the result was 102 (unspecified units) and also underwent blood test and the result looked good. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events sore tight muscles in arms and legs/ hard to get on/off toilet, hard to get up from sitting position, hard to walk, some days temperature will spike to 102, cold chills and hives were not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Muscle tightness, Myalgia, Urticaria
Clinical narrative: Sore tight muscles in arms and legs/ hard to get on/off toilet, hard to get up from sitting position; Sore tight muscles in arms and legs/hard to get on/off toilet, hard to get up from sitting position; Hard to walk, stopped taking stairs/ Hard to get on/off toilet, hard to get up from sitting position; Some days temperature will spike to 102; Cold chills; Hives; This is a spontaneous report from a contactable consumer, the patient. A 54-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6200) via an unspecified route of administration on 24Feb2021 at 09:00 (at the age of 54-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure, allergy to penicillin and sulfa. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medications included lisinopril (MANUFACTURER UNKNOWN) and cetirizine hydrochloride (ZYRTEC); both from an unknown date for an unknown indication. The patient previously received doxycycline (MANUFACTURER UNKNOWN) and cefdinir (MANUFACTURER UNKNOWN) and experienced drug allergy. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on an unknown date as a single dose for COVID-19 immunisation. On 26Feb2021, the patient experienced sore tight muscles in arms and legs, hard to get on/off toilet, hard to get up from sitting position, hard to walk, stopped taking stairs, some days temperature will spike to 102, sometimes got cold chills and have to get under 3-4 throws and sometimes have hives. It was reported that doctor did blood work which looked good and thought symptoms related to shot. It was reported that the patient had shot 9 weeks ago, at the time of this report. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events which included treatment with famotidine/ibuprofen (DUEXIS) 800 mg 3times a day. On an unknown date in 2021, the patient underwent body temperature test and the result was 102 (unspecified units) and also underwent blood test and the result looked good. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events sore tight muscles in arms and legs/ hard to get on/off toilet, hard to get up from sitting position, hard to walk, some days temperature will spike to 102, cold chills and hives were not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Dyspnoea, Dyspnoea exertional, Fatigue, Headache, Lethargy
Clinical narrative: Sore throat; Feverish; Moderate lethargy; Severe headaches; Moderately out of breath with workouts.; Localized mild aching of the site; localized mild aching of the site and discoloration; Mild overall tiredness/moderate overall tiredness; Slightly out of breath with regular tasks/moderately out of breath with daily activity; This is a spontaneous report from a contactable healthcare professional. A 26-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0170) via an unspecified route of administration in the left arm on 22Apr2021 at 17:45 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma, attention deficit hyperactive disorder (adhd), anxiety, depression and unknown autoimmune disorder. The patient previously received amoxicillin (MANUFACTURER UNKNOWN) for an unknown indication on an unknown date and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included lisdexamfetamine mesilate (VYVANSE), desogestrel/ethinylestradiol (APRI), sertraline hydrochloride (ZOLOFT), cyanocobalamin(B12) and colecalciferol (VITAMIN D3); all for unknown indication, from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 23Apr2021 at 12:00, day two the patient experienced localized mild aching of the site and discoloration, mild overall tiredness and slightly out of breath with regular tasks, day three (24Apr2021) moderate overall tiredness and moderately out of breath with workouts, day four (25Apr2021) severe headaches, moderately out of breath with daily activity, day five (26Apr2021) sore throat, feverish and moderate lethargy. Therapeutic measures were not taken as a result of adverse events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events localized mild aching of the site and discoloration, mild overall tiredness, slightly out of breath with regular tasks, moderately out of breath with workouts, severe headaches, sore throat, feverish and moderate lethargy were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Oropharyngeal pain, Pyrexia, Vaccination site discolouration, Vaccination site pain
Clinical narrative: Sore throat; Feverish; Moderate lethargy; Severe headaches; Moderately out of breath with workouts.; Localized mild aching of the site; localized mild aching of the site and discoloration; Mild overall tiredness/moderate overall tiredness; Slightly out of breath with regular tasks/moderately out of breath with daily activity; This is a spontaneous report from a contactable healthcare professional. A 26-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0170) via an unspecified route of administration in the left arm on 22Apr2021 at 17:45 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma, attention deficit hyperactive disorder (adhd), anxiety, depression and unknown autoimmune disorder. The patient previously received amoxicillin (MANUFACTURER UNKNOWN) for an unknown indication on an unknown date and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included lisdexamfetamine mesilate (VYVANSE), desogestrel/ethinylestradiol (APRI), sertraline hydrochloride (ZOLOFT), cyanocobalamin(B12) and colecalciferol (VITAMIN D3); all for unknown indication, from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 23Apr2021 at 12:00, day two the patient experienced localized mild aching of the site and discoloration, mild overall tiredness and slightly out of breath with regular tasks, day three (24Apr2021) moderate overall tiredness and moderately out of breath with workouts, day four (25Apr2021) severe headaches, moderately out of breath with daily activity, day five (26Apr2021) sore throat, feverish and moderate lethargy. Therapeutic measures were not taken as a result of adverse events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events localized mild aching of the site and discoloration, mild overall tiredness, slightly out of breath with regular tasks, moderately out of breath with workouts, severe headaches, sore throat, feverish and moderate lethargy were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: Tinnitus; This is a spontaneous report from a contactable nurse, the patient. A 50-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 06Jan2021 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. The medical history was not reported. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive other vaccines within four weeks prior to the vaccination. The patient did not receive any medications within two weeks of vaccination. On an unspecified date in 2021, the patient experienced tinnitus. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event tinnitus was unknown at the time of this report.    No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Bedridden, Hot flush, Lymphadenopathy, Pain
Clinical narrative: Swollen lymph nodeunder left arm,; Painful arm; Feeling weak; Hot and cold flashes; Strong body ache; Bound to bed; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 25May2021 at 16:30 as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies. Concomitant medications were not reported. The patient previously the first dose of BNT162b2 (COMIRNATY; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 04Apr2021 at 16:00 as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 26Apr2021 at 02:00, the patient experienced strong body ache. On 26Apr2021, the patient experienced bound to bed. On 27Apr2021, the patient experienced swollen lymph node under left arm, painful arm, feeling weak and hot/cold flashes. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the events. The clinical outcome of the events strong body ache was recovered on 26Apr2021. The clinical outcome of the event bound to bed, swollen lymph node under left arm, painful arm, feeling weak and hot/cold flashes was recovering at the time of report. No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Swollen lymph nodeunder left arm,; Painful arm; Feeling weak; Hot and cold flashes; Strong body ache; Bound to bed; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 25May2021 at 16:30 as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies. Concomitant medications were not reported. The patient previously the first dose of BNT162b2 (COMIRNATY; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 04Apr2021 at 16:00 as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 26Apr2021 at 02:00, the patient experienced strong body ache. On 26Apr2021, the patient experienced bound to bed. On 27Apr2021, the patient experienced swollen lymph node under left arm, painful arm, feeling weak and hot/cold flashes. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the events. The clinical outcome of the events strong body ache was recovered on 26Apr2021. The clinical outcome of the event bound to bed, swollen lymph node under left arm, painful arm, feeling weak and hot/cold flashes was recovering at the time of report. No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.